
AbbVie’s Mavyret scores FDA label expansion to shorten treatment duration for hepatitis C patients
pharmafile | September 27, 2019 | News story | Medical Communications, Sales and Marketing | AbbVie, FDA, hepatitis, hepatitis C, mavyret, pharma
The FDA has chosen to expand the existing label for AbbVie’s Mavyret (glecaprevir/pibrentasvir), it has been revealed, to include the treatment of previously untreated patients over the age of 12 who have chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection and compensated cirrhosis.
The approval will see the duration of treatment with the drug shortened from 12 to eight weeks.
The US regulator authorised the therapy on the back on Phase 3b data in which 98% of 336 participants experienced a sustained virologic response after receiving the drug for 12 weeks. During the trial, just one relapse was recorded, with no patients halting treatment due to adverse events.
“While over 100,000 patients have been prescribed Mavyret for chronic HCV in the US, there are still a significant number of patients that need options,” explained Dr Janet Hammond, Vice President, General Medicine and Virology Therapeutic Area at AbbVie. “This approval provides more HCV patients an option to treat their disease in as little as eight weeks.”
Matt Fellows
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

FDA grants De Novo authorisation to light-filtering device for migraine
The US Food and Drug Administration (FDA) has granted De Novo marketing authorisation to Avulux, …






